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Abstract 
Background: Concerns regarding the safety of inactivated foot‑and‑mouth disease (FMD) vaccine have been raised 
since it is produced from cultured live FMD virus (FMDV). To overcome this issue, recombinant protein has been stud‑
ied as an alternative vaccine.
Results and conclusion: We designed a chimerical multi‑epitope recombinant protein (5BT), which is comprised of 
tandem repeats of five B cell epitopes (residue of VP1 136–162) derived from different FMDV variants and one T‑cell 
epitope (residue of 3A 21–35). To increase solubility and stability of 5BT, it was conjugated with BmpB, the membrane 
protein B of Brachyspira hyodysenteriae (B5BT). Our results indicated that 5BT was susceptible to degradation by host 
protease and produced with substantial fraction of inclusion body. The stability and solubility of 5BT was greatly 
increased by conjugating to BmpB. FMDV specific antibodies were observed in the serum of mice immunized with 
5BT and B5BT comparable to inactivated FMD vaccine. Sera from 5BT and B5BT groups also exhibited high epitope‑
specific antibody titers in peptide specific ELISA, indicating that all five epitopes are exposed to the B cell receptor for 
the antibody reaction. Thus the multi‑epitope recombinant protein designed in this study may be a potential candi‑
date as an alternative vaccine against FMDV epidemic variants.
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Background
Foot-and-mouth disease (FMD) causes loss of produc-
tivity of animals, leads to large-scale economic shock 
in livestock industries and induces disadvantages in 
national trade of livestock products as it causes an acute 
contagious disease to cloven-hoofed animals such as 
pigs, cattle, and sheep [1, 2]. Although many researchers 
have tried to prevent FMD, FMD virus (FMDV) is dif-
ficult to be eradicated because of its rapid mutation and 
variation. Seven different serotypes of FMDV (O, A, C, 
Asia-1, SAT-1, SAT-2, and SAT-3) have been identified, 
and rapid mutation rate of serotypes derived numerous 
variants of serotypes [3, 4]. Serotype O is known as the 
main serotype of FMDV breaking out in East Asia, Mid-
dle Asia, Africa and Europe [5].
Vaccination is considered as the only option to con-
trol and prevent FMD. Inactivated virus vaccine for the 
prevention of FMD has been commercialized [6]. How-
ever, it is expensive because the production of inacti-
vated vaccine requires a high level of biological safety 
facility to prevent the risk of leakage of live virus, and a 
long time to adapt the virus to cells. The inactivated vac-
cine is produced by only using the structure proteins 
(SPs) and removing the non-structure proteins (NSPs) 
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of FMDV, which can be obtained from killing the virus 
through chemical treatments. If the NSPs are not com-
pletely removed in the process, it would cause a serious 
biosafety concern, which would hinder efforts to employ 
serology to distinguish between infected and vaccinated 
animals (DIVA) [7, 8]. This fact leads to classifying all 
countries as FMD free with or without the use of vacci-
nation by OIE, world organization for animal health. For 
this reason, most of countries have introduced a policy of 
the stamping out of FMD infected animal to remain FMD 
free rather than employing vaccination [2].
Subunit vaccines that consist of recombinant proteins 
produced in bacteria have been suggested as an alterna-
tive to solve these problems [6]. These vaccines are free 
from DIVA biosafety concern and easy for mass produc-
tion. However, subunit vaccines with fixed amino acid 
sequence may have limited efficacy for certain FMD 
strains because of high mutation rates. For this reason, 
antibodies produced by existing subunit vaccines have 
low specificity for neutralizing the mutated FMDV [9]. 
To overcome this weakness, many researchers have tried 
to produce newly designed recombinant subunit vaccines 
which are more effective to FMD [10].
We designed a multi-epitope FMD vaccine candi-
date composed of five B-cell epitopes and one T-cell 
epitope to address this variation problem. The technol-
ogy for construction of multi-epitopic proteins and their 
usage as vaccines has been already disclosed in a series 
of patent applications [11, 12]. In addition, several stud-
ies already showed that B-cell epitopes are important to 
produce neutralizing antibodies and T-cell epitopes are 
also necessary to enhance the immune response by acti-
vating T cells to develop a more efficient vaccine against 
FMDV [13–15]. GH loop (commonly known as amino 
acid residues 130–160) in VP1 of FMDV is a representa-
tive B-cell epitope containing RGD motif, which is an 
essential sequence to bind integrin of host animal cells 
for infection [13, 16, 17]. RGD motif region is conserved 
in most FMDV variants although the rest regions of GH 
loop are highly variable [4]. We selected five representa-
tive GH loop as B-cell epitope (amino acid residue 136–
162) among the epidemic strains existing throughout the 
world for wide protection against various FMDV vari-
ants considering its hyper-variability. We also introduced 
T-cell epitope (amino acid residue 21–35 of 3A protein) 
in one of FMDV NSPs in C-terminus of the protein to 
enhance the immune response of the subunit vaccine. 
The subunit vaccine composed of only B-cell epitopes 
is inadequate to induce an immune response because 
B cells activated by B-cell epitope need to be stimu-
lated by cytokine secreted from T cells to differentiate 
into plasma cells for producing antibodies. Blanco et al. 
proved that the T-cell epitope of 3A protein conjugated 
in C-terminus of the protein enhanced the immune 
response [18].
There are several huddles to producing artificial recom-
binant proteins in a soluble form using Escherichia coli 
system. Recombinant proteins expressed in E.coli often 
form inclusion bodies and, in some cases, are not accu-
mulated [19]. The use of fusion partner is a common 
method to overcome this problem. Recombinant proteins 
have improved the solubility and stability with the conju-
gating fusion protein [19, 20]. We introduced membrane 
protein B of Brachyspira hyodysenteriae (BmpB) which 
caused swine muco-hemorrhagic dysentery, as a fusion 
partner of multi-epitope subunit vaccine in N-terminus 
of the recombinant protein [21].
In this study, we designed a multi-epitope FMDV sub-
unit vaccine composed of five different B-cell epitopes 
from five FMDV type O variants conjugated to one 
T-cell epitope at C-terminus. To enhance the solubility 
and stability of this artificial peptide. BmpB was conju-
gated with N-terminus of the protein. Our results in this 
study will provide the strategic insight for cost-effective, 
easy handling, and wide spectrum FMDV subunit vac-
cine design.
Methods
Design of multi‑epitope FMD vaccines
Seventy-one peptide sequences of GH loop (residues 
136–162) of VP1 were collected from NCBI database, 
and hierarchical clustering for analyzing the amino acid 
sequence through R software (Fig.  1) was performed. 
The final selection was conducted to include one rep-
resentative GH loop sequence from each major cluster 
in the phylogenetic tree. A T-cell epitope (amino acid 
residues 21–35) was selected from 3A of type O FMDV 
(O-UKG 11/01) [18]. A 504 base pair (bp) synthetic 
gene, 5BT, which consists of five B-cell epitopes and 
one T-cell epitope in tandem array, was synthesized in 
pIDTSMART-AMP (IDT, CA, USA). This gene contains 
two Xho I restriction sites. To minimize interference 
between adjacent epitopes, each epitope was separated 
by two glycines, and T-cell epitope was separated from 
five B-cell epitopes by two glycines and one glutamate. 
5BT gene was cut out by Xho I and ligated with pET21a-
BmpB precut with Xho I [21] resulting in pET21a-BmpB-
5BT (B5BT). 5BT gene was amplified by PCR from the 
pIDTSMART-AMP using an upstream primer engi-
neered to introduce an Nde I site (5′- AATTTTACCA-
TATGGGTGGGAGTTATGGCAA ATCCCC-3′) and 
a downstream one with a Xho I site (5′-GATCCGCTC-
GAGTTTGATGGACGG -3′). PCR product was cloned 
into Nde I and Xho I of pET21a precut with the same 
enzymes, resulting in pET21a-5BT. The recombinant 
plasmids were confirmed by DNA sequencing at the 
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National Instrumental Center for Environmental Man-
agement (NICEM, Seoul, Korea).
Protein expression and purification
The vectors were transformed into E. coli BL21 (DE3) 
(Novagen, CA, USA) using heat-shock transformation at 
42  °C. And, 7 ml of overnight culture was inoculated in 
1 L of Luria–Bertani (LB) broth containing 100 ng/ml of 
ampicillin in 2.8L Fernbach flask. Cultures were agitated 
at 230  rpm until A600 reached 0.6 and expression was 
induced with 1 mM isopropyl-β-d-thiogalactopyranoside 
(IPTG) for 4  h at 37  °C. Cells were harvested by cen-
trifugation at 6500  rpm for 10  min at 4  °C. Cell pellets 
were resuspended in 100 ml of binding buffer (500 mM 
NaCl, 5  mM imidazole, 20  mM Tris–HCl, pH 7.9) and 
sonicated on ice (48 × 10 s). Lysates were centrifuged at 
17,000 rpm at 4 °C for 20 min and supernatants (soluble 
fraction) were filtered through a 0.45 µm filter (Corning, 
NY, USA). 100 ml of binding buffer was added to soluble 
fraction to purify two target proteins, 5BT and B5BT. The 
5 ml bed volume of Ni-nitrilotriacetic acid (NTA) agarose 
resin (Novagen, CA, USA) was packed into a column and 
equilibrated with binding buffer. The sample was loaded 
into a column and the column was washed with 20 resin 
volume of binding buffer followed by 10 resin volume of 
wash buffer (40 mM imidazole, 0.5 M NaCl, 20 mM Tris–
Cl, pH 7.9). Target protein was eluted with 20 ml of elu-
tion buffer (1 M imidazole, 0.5 M NaCl, 20 mM Tris–Cl, 
pH 7.9). The eluted protein was dialyzed using a mem-
brane tube (molecular cut-off: 6–8000  kDa, Spectrum, 
CA, USA) against the distilled water at 4  °C overnight. 
Desalted solution was lyophilized and stored at −20  °C 
until used. Lipopolysaccharide (LPS) was removed using 
ToxinEraser™ Endotoxin removal kit (Genscript, NJ, 
USA) and detected by using ToxinSensor™ Chromogenic 
LAL endotoxin assay kit (Genscript, NJ, USA). OD280 
was detected by a spectrophotometer (Implen, Munchen, 
Germany) and protein concentration was calculated 
using extinction coefficient [22]. To analyze the inclu-
sion body formation, sonicated cell debris was dissolved 
in 100  ml of solubilization buffer (10  mM tris-base, pH 
12.5) and centrifuged at 17,000  rpm at 4  °C for 20 min. 
Supernatant containing dissolved inclusion body (inclu-
sion body fraction) was transferred to other tubes.
Analysis of solubility and stability of recombinant proteins
The 20  µl of soluble and inclusion body fractions were 
analyzed by 15% sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis (SDS–PAGE). The gels were stained 
with Coomassie Brilliant Blue by 3 times of heating in 
a microwave oven for 70 s, cooled down on a rocker for 
5 min and destained with 25% methanol and 7.5% acetic 
acid solution overnight. Bands were analyzed by image J 
software (NIH) to compare target protein quantity [23]. 
The target protein was confirmed by western blot assay 
using His-tag antibody (Abcam. MA. USA). The protein 
was separated in a 15% SDS–PAGE and then transferred 
to a nitrocellulose membrane (Whatman, Germany). The 
membrane was blocked by 5% skim milk in tris buffered 
saline (TBS) contacting 0.05% Tween 20 (TBST) for 1 h 
on a rocker and then washed three times with TBST. 
The membrane was incubated with a 1:1000 diluted his-
tag antibody overnight at 4  °C, washed three times with 
TBST, and incubated with a 1:2000 dilution of rabbit anti-
mouse IgG antibody conjugated with horseradish perox-
idase (HRP) (Abcam, MA, USA) for 1  h. After washing 
three times with PBST, the signal was developed tetra-
methylbenzidine (TMB). To test stability of the proteins, 
the cell pellets from 50  ml culture were resuspended in 
10  ml of PBS and distributed in 1  ml aliquot into the 
micro tube. The tubes were centrifuged at 13,000  rpm 
for 1 min at ambient temperature. The supernatant were 
Fig. 1 Phylogenetic tree via the correlation analysis of seventy‑one GH loop sequence (reside 136–162) from FMDV type O VP1 protein. Height, 
y axis means the number of different amino acids among GH loops. Open square boxes mean variant cluster and arrows indicate five sequences 
incorporated in 5BT design
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removed and cell pellets were stored at −70 °C until use. 
Every day one frozen tube was resuspended in 1  ml of 
PBS, sonicated and supernatants after centrifugation 
were stored at 4 °C. This was repeated for 7 days to inves-
tigate the protein degradation by endogenous proteases 
of E. coli. After 7  days proteins were analyzed by 15% 
SDS–PAGE, bands of target proteins in gel images were 
analyzed by Image J software.
Mouse immunization
Six-week old BALB/C mice were used for the immu-
nization following the policy and regulations for the 
care and use of laboratory animal (Laboratory Animal 
Center, Seoul National University, Korea). All of the pro-
tocols were reviewed and approved by the Animal Care 
and Use Committee at Seoul National University (SNU-
141201-1). The mouse was immunized intramuscularly 
at days 0, 14 and 28 with 20 µg (0.5 µg/µl) of each pep-
tide emulsified in Complete Freund`s Adjuvant (CFA, 
priming) or Incomplete Freund`s Adjuvant (IFA, boost-
ing) and sacrificed on day  42. Five mice in the negative 
control group were immunized with PBS and positive 
control group of 5 mice were immunized with 40  µl of 
inactivated FMDV vaccine (iFMDV, Daesung, Gyeonggi-
do, Korea). Blood samples were collected before priming 
(day 0) and on days 13, 27, and 42 (Sacrifice) from intra-
petrosal veins with a disposable syringe and delivered 
into sterilized tube. Serum was separated by centrifuga-
tion at 12,000 rpm for 3 min using serum separate tube 
(BD microtainer, NJ, USA).
ELISA assay
Antibody production was examined by ELISA in serum 
samples collected at days 0, 13, 27, and 42. Briefly, 96 well 
immuno-plate was coated with purified 5BT in carbon-
ate-bicarbonate buffer (CBB) for 1 h at 37 °C (0.1 µg/well) 
or to evaluate peptide specific antibody production about 
five B cell epitopes in the 5BT were separately synthe-
sized (Peptron, Daejeon, Korea) and dissolved in DMSO. 
Plates were coated with 50 ρmole/well of each peptide in 
the CBB. Then, wells were washed with PBS and blocked 
with 0.5% skim milk in PBS for 1  h at room tempera-
ture (RT). Series of fivefold dilution of each serum sam-
ple were prepared, starting at 1/50 and volume adjusted 
to 100 µl with PBST (0.5% tween 20 in PBS) containing 
0.5% skim milk. Plates were incubated for 2 h at RT and 
HRP conjugated goat anti-mouse antibody diluted 1:5000 
in PBST containing 0.5% skim milk was added. The color 
was developed with 100 µl/well of the TMB (Sigma, MO, 
USA) and stopped by an equal volume of 0.16 M H2SO4. 
Plates were read at 450 nm in a Microspectrophotometer 
(Tecan, Austria). Titer of specific antibody was calculated 
by Softmax Pro version 5.4.1. Antibody titers were 
reported as log10 of the reciprocal of the highest dilution. 
Serum of days 0, 13, and 27 were analyzed with above 
methods according to time by detecting 5BT specific IgG 
titers.
In addition, anti-FMDV O type antibodies were 
detected by competition ELISA using VDPro FMDV type 
O ELISA kit (Median diagnostics, Gangwon-do, Korea), 
following the manufacturer’s protocol. Briefly, each plate 
of the kit was pre-coated with FMDV type O P13C pro-
tein. Serum sample, negative control, and positive con-
trol were diluted by 1:5 in dilution buffer and prepared 
samples were incubated in wells for 1 h at RT. Then, wells 
were washed with washing buffer, 100 µl of HRP conju-
gated anti-FMDV antibody was added and samples were 
incubated for 1 h at RT. Color was developed with 100 µl/
well of the TMB substrate and stopped by 50 µl of stop 
solution. All reagents were provided in the kit. Plates 
were read in a Microspectrophotometer at 450  nm. PI 
(%) means the percent inhibition [24].
Statistical analysis
Statistical analysis was performed using OriginPro 9.0 
software (OriginLab, USA). For the significance of tests, 
a one-way analysis of variance (ANOVA) followed by 
Tukey’s post hoc test was used, and expressed as follows; 
*P < 0.05, **P < 0.01, ***P < 0.001.
Results
Design of the recombinant peptides and vector 
construction
We gathered sequence information of VP1, one of the 
structural proteins of FMDV type O, at NCBI GenBank 
and analyzed the amino acid sequence similarity of vari-
ous GH loop peptides (amino acid residues 136–162 of 
VP1) through hierarchical clustering (Fig.  1.). The pep-
tide sequences were classified into five clusters and one 
representative peptide of each cluster was selected to 
cover all five clusters of FMDV variants (Table  1). We 
constructed the recombinant plasmid which ligated the 
multi-epitope 5BT gene consisted of the selected five 
GH loops (B-cell epitopes) and one T-cell epitope into 
pET21a and pET21a-BmpB for expression of 5BT and 
B5BT, respectively (Fig. 2a). The expressed proteins were 
purified by his-tag purification (Fig.  2b). The peptides 
except BSA were detected by western blotting assay using 
anti-His-tag antibody (Fig. 2c). The concentration of the 
acquired proteins were measured with the previously 
described method, protein extraction and purification 
[25]. It was determined that purified 5BT was produced 
by 42  mg per litter culture and purified B5BT was pro-
duced by 11.6 mg per litter culture.
Page 5 of 10Lee et al. Microb Cell Fact  (2017) 16:33 
Characterization of proteins
To examine the effect of BmpB as a fusion partner, the 
soluble and insoluble fractions of 5BT, B5BT and BmpB 
were prepared and analyzed by SDS–PAGE (Fig. 3a). The 
previous report showed that BmpB was expressed fully 
as a soluble protein [21]. The ratio of soluble and inclu-
sion body fraction were analyzed by image J software 
(Fig. 3b). 5BT protein was produced mostly in the solu-
ble form. Although 5BT were mostly produced in soluble 
form, approximately 36% of 5BT were produced as the 
inclusion bodies. We introduced fusion partner, BmpB, 
into 5BT to improve the solubility of protein. B5BT con-
jugated BmpB in N-terminus of 5BT was expressed as 
98% of soluble protein. Though 5BT was expressed into 
soluble protein by introducing B-cell epitope containing 
secondary structure sequence, most of other 5BT region 
was unstructured in native VP1 and thus, a potentially 
unstable structure was predicted. As predicted, the 5BT 
proteins were degraded when incubated the crude pro-
tein extracts at 4 °C (Fig. 4a). 5BT rapidly degraded with 
45% loss in 24 h whereas BmpB and B5BT were stable for 
at least 6 days (Fig. 4b). Thus BmpB as a fusion partner 
increased the solubility of 5BT and protected the artifi-
cial proteins against endogenous host proteases.
Evaluation of multi‑epitope 5BT and B5BT as antigens
The immunogenic effect of 5BT and B5BT as subunit vac-
cines was tested in mice via the intramuscular injection. 
PBS and inactivated FMD vaccine (iFMDV) were used as 
a negative and a positive control. 5BT specific antibod-
ies were determined by ELISA in the serum collected at 
Table 1 Information of  B cell epitopes and  T cell epitope 
used in this study
Outbreak nation, year, NCBI accession number of FMDV and amino acid 
sequences included in 5BT design
No Year Accession  
number
Country Peptide sequence Note
A 2000 abv53920 China YGKSPVTNLRGDLQV‑
LTQKAARTLPTS
VP1
B 1963 acc63126 Belgium YSRNAVPNLRGDLQV‑
LAQKVARTLPTS
VP1
C 2000 cac51271 Korea YGESPVTNVRGDLQV‑
LAQKAARTLPTS
VP1
D 2010 afd50726 Korea YAGGSLPNVRGDLQV‑
LAQKAARPLPTS
VP1
E 2010 aaq92301 Kenya YGRAPVTNVRGDLQV‑
LAQKAARTLPTS
VP1
F 2001 abu63090 England AAIEFFEGMVHDSIK 3A
Fig. 2 a Schematic diagram for construction of recombinant 
proteins expression vector system. b SDS–PAGE gel stained with 
Coomassie Brilliant Blue. Each lane was loaded with 2 µg of purified 
recombinant proteins. Lanes: M, proteins marker; 1, 5BT (18.1 kDa); 
2, B5BT (45.8 kDa); 3, BmpB (28.7 kDa); 4, BSA (66.5 kDa). c Western 
blot analysis recombinant proteins were detected with His‑tag using 
anti‑His‑tag antibody. BmpB is a positive control and commercial BSA 
is a negative control
Fig. 3 SDS–PAGE analysis for the expression pattern of recombinant 
proteins. Lanes: M, protein marker; S, soluble crude protein; IB, crude 
inclusion bodies; 5BT, 18.1 kDa; B5BT, 45.8 kDa; BmpB, 28.7 kDa. The 
stained gel was analyzed by image J software and inclusion body 
fractions were: 5BT, 36%; B5BT, <2%; BmpB, <1%
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days 0, 13, 27 and 42 after priming immunization (Fig. 5a, 
b). 5BT specific antibodies increased in 5BT, B5BT, and 
iFMDV injection group. 5BT specific antibody titer was 
the highest in 5BT group compared to B5BT or iFMDV 
group which has the lowest one.
Figure 5 showed that antibodies produced in the group 
injected iFMDV, vaccine produced with MANISA O1 
strain, recognized 5BT although it does not contain GH 
loop peptide of MANISA O1. Furthermore, BmpB fusion 
did not affect the production of 5BT specific antibod-
ies in B5BT group. To evaluate the route of immune 
response, total IgG and IgG subtype (IgG1 and IgG2a) 
titers were determined using day 42 (Fig. 5c–e). All treat-
ment groups induced the balanced immune response of 
IgG1 and IgG2a, which indicates the balanced activation 
of Th1 and Th2 route.
Evaluation of multi‑epitope 5BT and B5BT as subunit 
vaccine
Anti-FMDV type O antibodies were evaluated using a 
liquid phase block (LPB) ELISA (Fig. 6a). Structure pro-
teins originated from MANISA O1 strain (iFMDV) were 
coated on the wells of the immuno-plate for competition 
ELISA. Antibodies in the serum of three groups were sig-
nificantly higher compared to the PBS group. Although 
FMD vaccine contained more epitopes other than GH 
loop compared to 5BT proteins, there was no significant 
difference between the iFMDV and 5BT or B5BT group 
in this competition assay. Sera of 5BT and B5BT group 
successfully compete with commercial antibodies that are 
bound to VP1 protein of FMDV in competition ELISA.
The accessibility of B-cell receptors was estimated using 
an ELISA to each GH loop peptide of 5BT for the produc-
tion of epitope specific antibody (Fig. 6b). If epitopes are 
exposed on the surface of a protein, it may lead to higher 
B-cell specific antibodies than those buried inside the 
protein. All epitopes of 5BT lead to produce their specific 
antibodies. Sera from 5BT and B5BT groups showed the 
similar peptide specific antibody titers with anti-BEL 63 
antibodies being the lowest among the groups. Sera of 
iFMDV group reacted very similarly to all GH loop pep-
tides of 5BT.
Discussion
The shortcomings such as high production cost, safety 
issue, and low protection rate due to high mutation rate 
of FMDV of chemically inactivated vaccine have been 
discussed to prevent FMD for a long time. Various strate-
gies were brought up to overcome these problems. Subu-
nit vaccine is the safest and the cheapest among them [6]. 
Especially, production of recombinant proteins in E. coli 
as bioreactor was most popular and the protocols were 
standardized [26]. The popularity of E. coli system comes 
from relatively inexpensive development procedures, 
simple cultivation procedures, and easy extraction of 
recombinant proteins [27].
Many researchers developed subunit vaccines to pre-
vent FMD and showed that multi-epitope vaccine was 
the best strategy for the livestock industry. [18, 28–30]. 
This concept has been already developed and publicly 
disclosed in a series of patent applications [11, 12]. Func-
tions and structure of the proteins consisted of FMDV 
have been thoroughly studied. VP1, a structure protein, 
has a GH loop region which binds to integrin of host cells 
and causes infection of animals. The surface region of 
VP1 containing GH loop has been related to neutralizing 
antibodies [31]. VP1 containing the linear and conforma-
tional epitope region is a good subunit vaccine candidate 
comparable to the effect of inactivated vaccine [32, 33]. 
However, it was reported that whole VP1 was produced 
in inclusion body form in E. coli [34, 35]. Inclusion body 
was produced by aggregation of miss folded proteins. 
Fig. 4 BmpB effect on the stability of recombinant proteins. a SDS–PAGE gel stained with Coomassie Brilliant Blue. Crude protein extracts were 
incubated at 4 °C for 6 days and daily sample was analyzed by SDS–PAGE. Lanes: M, protein marker. b Graph showing intact proteins in (a) analyzed 
by image J software
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Aggregated proteins have low bioactivity because it 
has insoluble character. In this reasons, many research-
ers have tried to make soluble protein from inclusion 
bodies using high concentration of urea and acetone 
precipitation [36–39]. Therefore, solubilization is very 
important step for the production of subunit vaccine, and 
the addition of re-solubilizing step increases the produc-
tion cost.
Fig. 5 Validation of recombinant proteins as FMDV subunit vaccine in vivo. a Schematic view of immunization and blood sapling schedule (n = 5/
group). b Antibody titer analysis by ELISA. Specific antibody titers against 5BT was measured by ELISA in serum samples collected at days 0, 13, 
27 and 42 post‑immunization. Antibody titers were expressed as the reciprocal log10 of the last dilution calculated by interpolation to give an 
absorbance of 1 above background. Each point corresponds to the geometric mean of each groups. Error bars represent standard error of the mean. 
Validation of immune response route of recombinant proteins. c 5BT specific total IgG titers detected by ELISA at day 42 post‑immunization, d 
IgG1, and e IgG2a. Endpoint titers were expressed as the reciprocal log10 of serum dilutions. Each symbol represents the value of individual mouse. 
Horizontal lines indicate the mean of each group of animals
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It cannot be predicted whether the artificial protein 
5BT is expressed in soluble or inclusion body form, or 
not accumulated in the recombinant host cells because 
this peptide is an artificially designed protein that does 
not exist in nature. We also designed and tried to express 
the recombinant protein containing five B cell epitopes 
covering amino acid residues 132–151. However, this 
construction was not expressed in E. coli (data not 
shown). There is a classical hypothesis for the mechanism 
of folding in which secondary structure, such as heli-
ces, turns, and sheets, are formed first and then dock to 
form the tertiary structure [40]. We thought that peptide 
(amino acid residues 136–162) containing the second-
ary structure region might help the structural formation 
of artificially designed protein. It was reported that in 
VP1 3D structure, GH loop region (amino acid residues 
136–162) is mostly un-structured on the surface of VP1 
[41], except 8 amino acids (amino acid residues 148–155) 
following RGD motif which forms alpha-helical struc-
ture [13]. Thus, the expression vector was constructed to 
cover GH loop region of the secondary structure (amino 
acid residue 136–162 of VP1), and 5BT protein was pro-
duced mostly in soluble form.
Though 5BT are mostly produced in soluble form, 
about 36% of 5BT was produced as the inclusion body. 
Moreover, 5BT was unstable in crude protein extract 
and degraded in the production process. In most organ-
ism, miss-folded and unstable proteins are degraded by 
endogenous protease [42, 43]. This makes it complicated 
to produce and store the recombinant subunit vaccine 
candidate, e.g. cell harvest and purification steps. To 
overcome this problem, BmpB was introduced as a fusion 
protein for the solubility and stability of 5BT. Conjuga-
tion of the fusion protein is one of methods frequently 
used to express soluble protein by improving the stable-
structure. The BmpB is known to express in soluble form 
in large amount in E. coli, and the result indicated that 
BmpB could resist to endogenous protease. In addition, 
the B5BT will be able to use as a conjugate vaccine for 
the prevention of FMDV and Brachyspira hyodysenteriae 
that causes swine dysentery. The stability and solubility 
of 5BT protein were greatly improved by BmpB conjuga-
tion although the expression level was lower compared to 
5BT alone. However, this can be overcome by controlling 
culture conditions, culture temperature, induction time, 
inducer concentration, and harvest time [26]. Further-
more, it may be possible that re-cloning with a codon 
optimized fusion partner BmpB will improve the expres-
sion level, which will perform the experiment in a near 
future.
From the mouse immunization experiment four results 
were noteworthy for effects of the artificial proteins. 
Firstly, 5BT specific antibodies were detected in the sera 
of 5BT and B5BT groups. B cell recognizes an epitope 
of antigens with B cell receptors and is activated by 
cytokines from T cells. Activated B cell differentiates into 
plasma cells which secrete antibodies. The antibodies 
bind to the epitope recognized by B-cell receptors [44]. 
B-cell epitopes should be exposed on the surface of anti-
gen for recognition by B-cell receptors [45]. It is indicated 
that 5BT region of B5BT is exposed and BmpB does not 
hinder the epitope access by B cell receptors. Secondly, 
Fig. 6 a Detection of FMDV specific antibody response in serum analyzed by competition ELISA assay at day 42 post‑immunization. The PI (%) 
means the percent inhibition. [PI = 100–100 × (OD450 of sample serum/OD450 of negative control)]. Negative and positive controls were satisfied 
with standard recommending of manufacturer manual. Each symbol represents the value for individual animals. Horizontal lines describe the mean 
value for each group of animals. **: P < 0.01; ***: P < 0.001, one way ANOVA. b Antibody response to each peptide in 5BT in serum analyzed by ELISA 
assay at day 42 post‑immunization. Antibody titers were expressed as the reciprocal log10 of the last dilution calculated by interpolation to give an 
absorbance. Error bars represent standard deviation
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although 5BT does not have the GH loop sequence of 
Manisa O1 strain (Table 1), which is the source of iFMDV 
vaccine, the sera of iFMDV group showed specific bind-
ing to 5BT and B5BT probably through the antibodies 
recognizing the conserved region containing RGD motif. 
It also suggest that 5BT and B5BT vaccine can protect 
other strain not included in 5BT through the reaction 
to this conserved region. Multi-epitope subunit vaccine 
has an effect of high density epitope to improve chances 
of recognition from B cell receptor [46]. It is important 
to prevent a wide spectrum of FMD variants. Thirdly, it 
was confirmed that immunization with 5BT and B5BT 
elicited the production of FMDV neutralizing antibod-
ies in mice. Sera of 5BT and B5BT groups successfully 
completed with commercial antibodies that bound to 
VP1 protein of FMDV in competition ELISA kit [24]. It 
was confirmed that immunization with 5BT and B5BT 
elicited the production of meaningful antibodies such 
as neutralizing antibodies against FMDV, in animals. 
Lastly, antibodies from all three antigenic groups showed 
more or less similar specific binding affinity to each syn-
thetic peptide composed of 5BT. Although exposure 
of epitope is influenced by protein folding pattern [45], 
B5BT and 5BT groups showed similar results. It means 
that BmpB increases the solubility and stability of 5BT 
without the conformational binding inhibition. In both 
5BT and B5BT groups, BEL63 specific antibody had the 
lowest titers compared to other peptides. 5BT protein 
is expected to have the secondary structure of the linear 
and alpha helix repeating five times and a terminal T cell 
peptide. Kloss et  al. suggested insight of protein struc-
tures consisting of repeating peptides. Adjacent repeats 
packed together in a more-or-less linear array, facilitat-
ing a simple linear representation of energetics, similar 
to that of DNA double helix formation. 5BT proteins or 
5BT region in B5BT might form single super secondary 
structure loop [47]. It is suggested that BEL63 epitope in 
the second position from N-terminus of 5BT may be least 
exposed to the B-cell receptors for the antibody reaction.
Conclusion
In conclusion, an artificial peptide containing five dif-
ferent epitopes from worldwide FMDV epidemic strains 
ware designed and successfully expressed in soluble and 
stable form in E. coli. Through immunization of purified 
protein in mice, the peptide`s potential as a FMD subunit 
vaccine candidate was verified. The study provides insight 
about the design and selection of multipotent artificial 
recombinant protein as a vaccine for a highly mutable 
viral disease such as FMD. In the future, immunization 
assay should be performed in cloven-hoofed animals for 
greater efficacy, and other vaccine development protocols 
should be employed.
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